. 2022 Sep 25;11(19):5643. doi: 10.3390/jcm11195643

Table 2.

Sensitivity analyses of the association between statin use and all-cause mortality.

	All Studies (n = 56)						Without Influential Studies (n = 50)
Subgroup	No. of Studies	Estimate (HR)	95% CI	Prediction Interval	I² (%)	p Value	No. of Studies	Estimate (HR)	95% CI	Prediction Interval	I² (%)	p Value
CVD	23	0.73	0.66–0.76	0.51–1.04	92	0.598	22	0.72	0.66–0.78	0.53–0.97	73	0.497
Non-CVD	33	0.70	0.67–0.79	0.49–1.02	95		28	0.74	0.71–0.78	0.60–0.91	71
CVD	23	0.73	0.67–0.79	0.51–1.04	92	0.179	22	0.72	0.66–0.77	0.53–0.97	73	0.525
CKD	6	0.69	0.63–0.75	0.55–0.85	61		5	0.72	0.67–0.77	0.64–0.81	1.2
Inflammatory disease	6	0.78	0.72–0.85	0.63–0.96	39		6	0.78	0.72–0.85	0.63–0.96	39
Cancer	3	0.77	0.64–0.92	0.07–7.52	94		3	0.77	0.64–0.92	0.07–7.52	94
Other	18	0.68	0.60–0.76	0.40–1.13	96		14	0.72	0.66–0.78	0.54–0.95	67
Asia	25	0.67	0.61–0.73	0.45–0.98	83	0.044	22	0.71	0.67–0.74	0.62–0.80	51	0.126
Australia	2	0.78	0.62–0.97	-	73		2	0.78	0.62–0.97	-	73
Europe	12	0.71	0.62–0.79	0.46–1.06	92		11	0.69	0.61–0.77	0.47–1.00	79
North America	17	0.78	0.73– 0.83	0.60–1.02	96		15	0.78	0.72–0.83	0.61–0.98	68

CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; HR, hazard ratio. p values were derived from the Q test for subgroup differences.